What happens when the anabolic party is over? Well, it turns out the hangover is real. Once osteoanabolic therapy like teriparatide or romosozumab comes to a screeching halt, the benefits don’t just stick around. They fade away faster than your New Year’s resolutions. Research shows that without follow-on therapy, bone mineral density (BMD) starts to decline—up to 4% a year. Ouch.
Stop taking those anabolic medications, and skeletal benefits vanish in a hurry. It’s like watching a slow-motion train wreck. Fracture risks? They climb back up, too. The thrill of reduced vertebral and non-vertebral fractures? Gone. How fun. Discontinuation means a gradual deterioration unless bisphosphonates or denosumab jump in to save the day.
Discontinuing anabolic meds? Watch skeletal benefits vanish and fracture risks soar—it’s a recipe for disaster.
Now, here’s the kicker: using alendronate after teriparatide can preserve those hard-won BMD gains. It’s like a lifeline thrown to a floundering swimmer. Denosumab does the same. But without timely antiresorptive consolidation, those sweet BMD benefits are just a memory.
And let’s not forget about abaloparatide. Following it up with alendronate? That’s a recipe for improved BMD and reduced fracture risk.
In the grand scheme of bone health, sequential therapy matters. Osteoanabolics pump up bone formation, while antiresorptives play defense by reducing remodeling. It’s a dance—one that needs both partners.
Yet, a second course after bisphosphonates? Not so great. Responses get muted.
